Significant Stock Offering Announcement by Harmony Biosciences
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced a major underwritten public offering. This offering will consist of up to 8,000,000 shares of the Company’s common stock. Importantly, this initiative is being spearheaded by the Selling Shareholders, Marshman Fund Trust II and Valor IV Pharma Holdings, LLC.
Details of the Offering
The Selling Shareholders have expressed intentions to grant underwriters a critical 30-day period in which they can purchase an additional 1,200,000 shares of common stock at the public offering price, minus any applicable underwriting discounts and commissions. Notably, Harmony Biosciences will not be offering any shares and will not benefit from any financial proceeds from this public offering.
J.P. Morgan's Role in the Offering
J.P. Morgan is serving as the sole book-running manager for this significant offering. The shares are being presented as part of an effective shelf registration statement that was previously filed. This statement automatically became effective upon filing, allowing a smooth process for the proposed public offering.
How to Access Offering Documents
Investors and interested parties can obtain copies of the necessary documents, like the preliminary prospectus supplement and the accompanying base prospectus, free of charge. These can be accessed through the SEC's official website under the name of Harmony Biosciences or directly through J.P. Morgan Securities. For personalized inquiry, J.P. Morgan can be contacted via telephone or through their designated email channels.
The Company's Commitment to Innovation
Harmony Biosciences is deeply committed to developing innovative therapies that target rare neurological diseases. They understand the challenges faced by patients with limited treatment options. Founded in 2017 by Paragon Biosciences, LLC, the company focuses on ensuring that overlooked patients receive the treatments they desperately need.
A Vision for the Future
Through their commitment to empathy and groundbreaking science, Harmony Biosciences aims to create a brighter future for patients suffering from these conditions. Their work reflects a dedication to therapeutic innovations and promoting a supportive community that extends beyond just medicine.
Conclusion of Offering Provisions
This announcement serves solely as a prelude to the public offering and does not constitute an offer to sell or solicit offers to buy these securities in any jurisdiction where such transactions would be unlawful without prior registration under the securities laws governing that jurisdiction. Stakeholders are advised to remain updated on conditions that could affect the securities laws in their areas.
Frequently Asked Questions
What is the purpose of the stock offering by Harmony Biosciences?
The stock offering aims to facilitate selling shareholders in liquidating shares while the company itself will not receive any proceeds from this offering.
Who are the Selling Shareholders involved in this offering?
The Selling Shareholders include Marshman Fund Trust II and Valor IV Pharma Holdings, LLC, who are initiating this public offering.
What role does J.P. Morgan play in the public offering?
J.P. Morgan acts as the sole book-running manager, overseeing and facilitating the offering process.
Can I access offering documents for free?
Yes, interested parties can obtain necessary offering documents at no charge via the SEC’s website or directly from J.P. Morgan Securities.
What is the focus of Harmony Biosciences as a company?
Harmony Biosciences is dedicated to developing innovative therapies specifically aimed at treating patients with rare neurological disorders.
